Dov A. Goldstein MD - 09 Sep 2022 Form 4 Insider Report for NeuBase Therapeutics, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 09 Sep 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Sep 2022, 17:00:41 UTC
Prior SEC filing: 17 Sep 2021
Next SEC filing: 22 Sep 2022
Source filing: View source filing
Reporting owner signature: /s/ Dietrich A. Stephan, as attorney-in-fact for Dov A. Goldstein

Key filing fact

Dov A. Goldstein MD filed Form 4 for NeuBase Therapeutics, Inc. on 12 Sep 2022.

Key facts

This page summarizes Dov A. Goldstein MD's Form 4 filing for NeuBase Therapeutics, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Sep 2022, 17:00.

Change

Previous filing in this sequence was filed on 17 Sep 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

NBSE transaction Derivative

Stock option (right to buy)

Award

Transaction value: $0
Shares: +37,600
Change %
Price: $0.000000
Shares after: 37,600
Date: 09 Sep 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 37,600
Exercise price: $0.6000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

25% of the total shares shall vest on the first anniversary of September 9, 2022, and the remaining shares shall vest on an equal monthly basis over the following 36 months.

SEC remarks

The power of attorney under which this form was signed is on file with the Commission.